A study protocol is designed to measure adherence to SSE, cost, and resource management, as well as to determine the usefulness of polarized vs nonpolarized dermoscopy devices.
Therapeutic combinations of immune checkpoint blockade with targeted, oncolytic, or antiangiogenic approaches are promising for patients with cutaneous melanoma.
Changes 2 to 4 months after the start of therapy with pembrolizumab may predict long-term response and survival.
Gene expression analysis and the identification of a single gene or a signature correlated with patients’ outcomes could lead to improved patient stratification.
Researchers findings support the use of pembrolizumab in patients with resected stage III melanoma.